Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DBVT DBV Technologies	$9.19 -0.3%	$9.24	$2.20 ▼ $12.78	$251.58M	-0.63	191,385 shs	12,742 shs
FULC Fulcrum Therapeutics	$7.10 -3.8%	$6.02	$2.32 ▼ $10.13	$383.26M	2.4	918,717 shs	1.21 million shs
IPHA Innate Pharma	$1.85 -3.1%	$2.08	$1.29 ▼ $3.51	$170.53M	0.26	187,219 shs	3,484 shs
SKYE Skye Bioscience	$4.11 -3.3%	$2.38	$1.14 ▼ $8.26	$127.33M	1.69	479,709 shs	7.48 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DBVT DBV Technologies	0.00%	-2.29%	+10.66%	+34.68%	+129.34%
FULC Fulcrum Therapeutics	0.00%	+1.57%	+3.50%	+146.53%	+14.52%
IPHA Innate Pharma	0.00%	+2.78%	-14.35%	+3.93%	-4.64%
SKYE Skye Bioscience	0.00%	+90.28%	+105.71%	+158.00%	-48.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DBVT DBV Technologies	3.689 of 5 stars	4.4	3.0	2.7	2.5	0.6
FULC Fulcrum Therapeutics	0.2706 of 5 stars	1.3	0.0	1.3	2.5	0.0
IPHA Innate Pharma	3.2527 of 5 stars	3.8	5.0	2.7	1.7	0.0
SKYE Skye Bioscience	2.3736 of 5 stars	3.5	4.0	3.2	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DBVT DBV Technologies	2.80	Moderate Buy	$14.75	60.59% Upside
FULC Fulcrum Therapeutics	2.50	Moderate Buy	$6.29	-11.47% Downside
IPHA Innate Pharma	3.50	Strong Buy	$11.00	494.59% Upside
SKYE Skye Bioscience	3.00	Buy	$16.60	303.89% Upside

Current Analyst Ratings Breakdown

Latest SKYE, DBVT, IPHA, and FULC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	DBVT DBV Technologies	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$21.00
6/24/2025	SKYE Skye Bioscience	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00
5/29/2025	DBVT DBV Technologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell	$7.25
5/27/2025	DBVT DBV Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/27/2025	DBVT DBV Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$15.00 ➝ $21.00
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00
5/20/2025	SKYE Skye Bioscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/15/2025	FULC Fulcrum Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$10.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DBVT DBV Technologies	$4.15M	60.62	N/A	N/A	$1.42 per share	6.47
FULC Fulcrum Therapeutics	$80M	4.79	N/A	N/A	$4.51 per share	1.57
IPHA Innate Pharma	$21.77M	7.83	N/A	N/A	$0.11 per share	16.82
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	$2.25 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DBVT DBV Technologies	-$113.92M	-$4.92	N/A	N/A	N/A	-3,249.99%	-278.24%	-140.54%	7/29/2025 (Estimated)
FULC Fulcrum Therapeutics	-$9.73M	-$0.07	N/A	N/A	N/A	N/A	-0.20%	-0.19%	7/30/2025 (Estimated)
IPHA Innate Pharma	-$53.53M	N/A	0.00	∞	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)
SKYE Skye Bioscience	-$26.57M	-$0.82	N/A	N/A	N/A	N/A	-53.92%	-48.58%	N/A

Latest SKYE, DBVT, IPHA, and FULC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	SKYE Skye Bioscience	-$0.31	-$0.28	+$0.03	-$0.28	N/A	N/A
5/1/2025	Q1 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A
4/11/2025	Q4 2024	DBVT DBV Technologies	N/A	-$1.10	N/A	-$1.10	N/A	$0.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DBVT DBV Technologies	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DBVT DBV Technologies	N/A	0.72	0.72
FULC Fulcrum Therapeutics	N/A	28.71	28.71
IPHA Innate Pharma	2.52	2.60	2.60
SKYE Skye Bioscience	N/A	11.85	11.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DBVT DBV Technologies	71.74%
FULC Fulcrum Therapeutics	89.83%
IPHA Innate Pharma	0.16%
SKYE Skye Bioscience	21.09%

Insider Ownership

Company	Insider Ownership
DBVT DBV Technologies	1.44%
FULC Fulcrum Therapeutics	7.00%
IPHA Innate Pharma	31.89%
SKYE Skye Bioscience	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DBVT DBV Technologies	80	27.39 million	27.00 million	Optionable
FULC Fulcrum Therapeutics	100	53.98 million	50.20 million	Optionable
IPHA Innate Pharma	220	92.18 million	62.78 million	Not Optionable
SKYE Skye Bioscience	11	30.98 million	30.05 million	Optionable

SKYE, DBVT, IPHA, and FULC Headlines

Recent News About These Companies

Skye Bioscience (NASDAQ:SKYE) Given "Market Outperform" Rating at JMP Securities

June 26, 2025 | americanbankingnews.com

Positive week for Skye Bioscience, Inc. (NASDAQ:SKYE) institutional investors who lost 53% over the past year

June 25, 2025 | finance.yahoo.com

Skye Bioscience Shares Nimacimab "Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th ...

June 24, 2025 | manilatimes.netM

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes ... - Morningstar

June 24, 2025 | morningstar.comM

Skye Bioscience Launches "Anatomy of Progress" Video Series on Nimacimab Development for Obesity Treatment - Nasdaq

June 24, 2025 | nasdaq.com

Skye Bioscience (NASDAQ:SKYE) Receives "Market Outperform" Rating from JMP Securities

June 24, 2025 | marketbeat.com

Skye Bioscience Launches "Anatomy of Progress" Video Series on Nimacimab Development for Obesity Treatment

June 23, 2025 | quiverquant.comQ

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

June 23, 2025 | globenewswire.com

Skye Bioscience (NASDAQ:SKYE) Trading 23.1% Higher - Should You Buy?

June 20, 2025 | marketbeat.com

Skye confirms phase 2 data on nimacimab for obesity expected later this year

June 19, 2025 | msn.com

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions

June 17, 2025 | finance.yahoo.com

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

June 17, 2025 | globenewswire.com

Cantor Fitzgerald Weighs in on Skye Bioscience FY2026 Earnings

June 12, 2025 | marketbeat.com

Cantor Fitzgerald Predicts Skye Bioscience FY2026 Earnings

June 10, 2025 | marketbeat.com

Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Rating of "Buy" from Analysts

June 8, 2025 | marketbeat.com

Skye Bioscience, Inc. (NASDAQ:SKYE) Given Average Recommendation of "Buy" by Brokerages

June 8, 2025 | marketbeat.com

Skye Bioscience (NASDAQ:SKYE) Trading Up 24% - Here's What Happened

May 31, 2025 | marketbeat.com

3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies

May 23, 2025 | zacks.com

Skye Bioscience to Participate in Upcoming Investment Conferences

May 22, 2025 | globenewswire.com

Skye And Arecor Partner To Develop Advanced Nimacimab Formulation For Obesity Treatment

May 21, 2025 | nasdaq.com

Q&A: Next wave of obesity drugs may ‘afford a lot of advantages’

May 20, 2025 | healio.comH

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE, DBVT, IPHA, and FULC Company Descriptions

DBV Technologies NASDAQ:DBVT

$9.18 -0.03 (-0.27%)

Closing price 06/27/2025 03:58 PM Eastern

Extended Trading

$9.18 0.00 (0.00%)

As of 06/27/2025 05:48 PM Eastern

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Fulcrum Therapeutics NASDAQ:FULC

$7.10 -0.28 (-3.79%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$7.10 +0.01 (+0.07%)

As of 06/27/2025 04:34 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Innate Pharma NASDAQ:IPHA

$1.84 -0.07 (-3.40%)

As of 06/27/2025 04:00 PM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Skye Bioscience NASDAQ:SKYE

$4.11 -0.14 (-3.29%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.15 +0.04 (+0.97%)

As of 06/27/2025 07:58 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time